Efficacy of Dexamethasone Added to Ramosetron for Preventing Postoperative Nausea and Vomiting in Highly Susceptible Patients Following Spine Surgery

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01013012

Enrollment

Registered

2009-11-13

Start date

2008-01-31

Completion date

2008-11-30

Last updated

2012-02-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nausea, Vomiting

Keywords

highly susceptible patients following spine surgery

Brief summary

The purpose of this study is to study the efficacy of dexamethasone added to ramosetron for preventing postoperative nausea and vomiting in highly susceptible patients following spine surgery.

Interventions

DRUGramosetron with saline

Group A : saline 1 ml, ramosetron 6μg/kg

DRUGramosetron with dexamethasone

Group B : dexamethasone 4 mg, ramosetron 6μg/kg

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

NONE

Eligibility

Sex/Gender

FEMALE

Age

18 Years to 65 Years

Healthy volunteers

Yes

Inclusion criteria

* Females * Ages 18 to 65 years old

Exclusion criteria

* Patients who is taking steroid or who had been treated for the gastrointestinal disease * Patients who have troubles with the kidney or liver * Patients transferring to the ICU after the surgery * overfat patients * Patients who had taken antiemetics within 24 hours before the surgery

Design outcomes

Primary

Measure	Time frame	Description
the incidence of postoperative nausea and vomiting(PONV)	After spinal surgery	incidence of overall postoperative nausea and vomiting (PONV) between combination of ramosetron and dexamethasone and ramosetron alone in highly susceptible patients

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026